)
)
)
UroTech
UroTech is a molecular diagnostics and medtech company developing a first-in-class, urine-based in-vitro diagnostic platform for prostate cancer. Our proprietary mirCap™ technology captures and analyzes disease-specific RNA fragments directly from native urine, enabling non-invasive, accurate detection of prostate cancer.
The company has completed a clinical study in Korea demonstrating superior performance versus conventional PSA testing, particularly in reducing unnecessary biopsies. UroTech is now advancing global expansion through strategic partnerships, licensing, and co-development for the U.S. and European markets. Our development pathway includes an FDA Q-Sub strategy and a De Novo regulatory approach tailored for novel diagnostic algorithms.
Address
Cheongju citySouth Korea
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)